title: The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome.
abstract: The antitumor drug aclacinomycin A was previously shown to inhibit the degradation of ubiquitinated proteins in rabbit reticulocyte lysates with an IC50 of 52 microM (Isoe, T., Naito, M., Shirai, A., Hirai, R., and Tsuruo, T.(1992) Biochim. Biophys. Acta 1117, 131-135). We report here that from all the catalytic activities of the 20 S proteasome tested, the chymotrypsin-like activity was the only one affected by the antitumor drug. An important requirement for inhibition of the chymotrypsin-like activity seemed to be the presence of hydrophobic nonpolar residues in positions P1 to P3. Degradation of Z-E(OtBu)AL-pNA and Z-LLL-AMC at pH 7.5 was dramatically (87-98%) inhibited by 50 microM of the drug, while that of Z-GGL-pNA (containing uncharged polar residues in positions P2 and P3) and succinyl-LLVY-AMC (containing an uncharged polar residue in the P1 position) was inhibited only 11 and 24%, respectively. Aclacinomycin A had no effect on cathepsin B, stimulated trypsin, and inhibited chymotrypsin and, to a lesser extent, calpain. The aglycone and sugar moieties of the cytotoxic drug are essential for inhibition. The results presented here support a major role for the chymotrypsin-like activity in the degradation of ubiquitinated proteins. Aclacinomycin A is the first described non-peptidic inhibitor showing discrete selectivity for the chymotrypsin-like activity of the 20 S proteasome.
authors.affiliation: Department of Pharmacology, Mount Sinai School of Medicine of City University of New York, New York, New York 10029, USA.
authors.forename: M E
authors.initials: ME
authors.lastname: Figueiredo-Pereira
authors.forename: W E
authors.initials: WE
authors.lastname: Chen
authors.forename: J
authors.initials: J
authors.lastname: Li
authors.forename: O
authors.initials: O
authors.lastname: Johdo
mesh_terms: D015250:Aclarubicin / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000737:chemistry / Q000494:pharmacology*; D002384:Catalysis; D002417:Cattle; D002918:Chymotrypsin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D003546:Cysteine Endopeptidases / Q000187:drug effects* / Q000378:metabolism; D006868:Hydrolysis; D015394:Molecular Structure; D009097:Multienzyme Complexes / Q000187:drug effects* / Q000378:metabolism; D010902:Pituitary Gland / Q000201:enzymology*; D046988:Proteasome Endopeptidase Complex; D011506:Proteins / Q000378:metabolism*; D014452:Ubiquitins / Q000378:metabolism
chemical_list: D000903:Antibiotics, Antineoplastic; D009097:Multienzyme Complexes; D011506:Proteins; D014452:Ubiquitins; D015250:Aclarubicin; D002918:Chymotrypsin; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex